Transcriptome and Epigenome of TIL Infusion for Cancer Immunotherapy

Patients were either complete responders, or non-responders with rapid progression of disease. Thus stable disease, and partial responders were excluded. Patients who had received prior immunotherapy in the form of genetically engineered TIL, TCR treatments, and checkpoint-inhibitor anti-PD1 therapy were excluded. Informed consent was obtained and documented in accordance with the principles set forth in the Declaration
of Helsinki. Patients were required to be 18 years of age or older, to have measurable metastatic melanoma, to be of good performance status, to be free of systemic infections, to have received no prior anti-PD-1-targeting therapy, and to be eligible to receive high-dose IL-2 therapy. Patients were required to be eligible to receive total body irradiation (TBI). ]]>
NA]]>